中文产业新闻精选评分76Chinese source
强生首款口服多肽 IL-23 受体拮抗剂艾特雅在华获批
强生首款口服多肽靶向药艾特雅®在华获批
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
强生首款口服多肽靶向药艾特雅®在华获批
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.